Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor

NCT01283971 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01283971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01283971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Parallel-group Study of the Reduction of Signs and Symptoms During Treatment With Tocilizumab Versus Adalimumab, Both in Combination With MTX, in Patients With Moderate to Severe Active Rheumatoid Arthritis and an Inadequate Response to Treatment With Only One TNF Inhibitor
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Terminated
Start date
May 31, 2011
Completion date
August 31, 2012
Enrollment
96 (actual)
Sites
170

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis